Bitterman A et al., 2022-03: Meta-analysis of 12 trials (3901 patients) finding that the mortality benefit attributed to ivermectin tracked regional strongyloidiasis prevalence and disappeared where the parasite is not endemic.
No evidence was found to suggest ivermectin has any role in preventing mortality among patients with COVID-19 in regions where strongyloidiasis was not endemic.
Bitterman A et al., 2022-03: Meta-analysis of 12 trials (3901 patients) finding that the mortality benefit attributed to ivermectin tracked regional strongyloidiasis prevalence and disappeared where the parasite is not endemic. Meta-analysis with meta-regression; 12 randomized trials, 3901 patients, trials from 1 January 2019 to 6 November 2021, drawing on the c19ivermectin trial database; studies with suspected fraud or randomization failure excluded. Finding: relative risk fell 38.83% (95% CI 0.87%-62.25%) for each 5% increase in regional strongyloidiasis prevalence. Confound hypothesis: treating undiagnosed strongyloidiasis, not SARS-CoV-2. Disclosures: none reported. This is the published strongyloidiasis-confounding critique C5 asks for. Study type: review.
